Do you routinely treat oligoprogressive metastatic sites with SBRT in patients receiving systemic therapy and otherwise stable disease?   

We have been receiving referrals for oligoprogressive SBRT for multiple primary tumors (NSCLC, Colorectal, Renal Cell, etc.) in the setting of diffusely metastatic cancer. Usually these patients are on some form of immunotherapy or other targeted therapy.



Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Compass Oncology
Very well said. This is how we approach oligometas...
Radiation Oncologist at University of Toronto
Completely agree with excellent synopsis above by ...
Sign in or Register to read more